Perspective Therapeutics’ (CATX) “Outperform” Rating Reaffirmed at Wedbush

Perspective Therapeutics (NYSE:CATX)‘s stock had its “outperform” rating reissued by Wedbush in a research note issued on Wednesday,RTT News reports. They presently have a $11.00 target price on the stock. Wedbush’s price target points to a potential upside of 384.58% from the stock’s previous close.

A number of other research firms also recently weighed in on CATX. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a report on Wednesday, March 19th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Finally, Scotiabank started coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective on the stock. One analyst has rated the stock with a hold rating, eight have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, Perspective Therapeutics has a consensus rating of “Buy” and an average price target of $14.56.

Perspective Therapeutics Price Performance

Shares of NYSE:CATX traded down $0.20 during midday trading on Wednesday, reaching $2.27. The company had a trading volume of 738,740 shares, compared to its average volume of 991,089. The company’s 50 day moving average price is $3.00 and its 200 day moving average price is $6.57. Perspective Therapeutics has a 52-week low of $2.22 and a 52-week high of $19.05.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. The Manufacturers Life Insurance Company grew its stake in Perspective Therapeutics by 8.9% during the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after acquiring an additional 1,672 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Perspective Therapeutics by 5.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after purchasing an additional 3,211 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Perspective Therapeutics by 7.4% during the 4th quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company’s stock valued at $163,000 after purchasing an additional 3,529 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Perspective Therapeutics by 4.5% in the fourth quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock worth $303,000 after purchasing an additional 4,075 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of Perspective Therapeutics by 3.4% in the fourth quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company’s stock worth $458,000 after buying an additional 4,693 shares in the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.